ViaCyte to Present at Three Upcoming Healthcare Events

SAN DIEGO, January 19, 2018 ViaCyte, Inc., a privately-held regenerative medicine company, today announced participation in three upcoming healthcare events. ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes. The company’s lead PEC-DirectTM product candidate is in clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications.  The related PEC-EncapTM product candidate, and a candidate called PEC-QT based on the use of a gene edited immune-evasive cell line, are also in development and have the potential to provide a functional cure for essentially all patients with insulin-requiring diabetes, both type 1 and type 2.

Details of the events are as follows:

Phacilitate Cell & Gene Therapy World
Speaker: Dr. Mark Zimmerman, Vice President, Strategy and Business Development
Title: Case study: Developing a cell therapy combination product for diabetes
Date/Time: January 24, 4:05 PM ET
Location: Hyatt Regency, Miami, Florida

Arab Health Exhibition and Congress
Presenters: Dr. Paul Laikind, President and CEO, and Dr. Mark Zimmerman, Vice President, Strategy and Business Development
Date/Time: January 29 to February 1
Location: Johnson & Johnson Exhibit in the UAE Ministry of Health area; Dubai International Convention and Exhibition Centre, Dubai, United Arab Emirates

2018 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium
Speaker: Dr. Evert Kroon, Senior Director, Research Physiology
Session: Encapsulation and Mechanical Immunoprotective Approaches in Beta Cell Replacement
Title: Macroencapsulation Approaches
Date/Time: February 1, 8:45 AM PT
Location: The Langham Huntington, Pasadena, California

For more information about ViaCyte’s participation in industry events, please visit:

About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in durable and retrievable cell delivery devices.  Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels.  ViaCyte has two product candidates in clinical-stage development.  The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes.  The PEC-Encap™ (also known as VC-01) product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin.  ViaCyte is also developing immune-evasive ‘universal donor’ stem cell lines, from its proprietary CyT49 cell line, expected to further broaden the availability of cell therapy for diabetes and other indications.  ViaCyte is headquartered in San Diego, California.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.